Vaxart, Inc. · OTC:VXRT
Vaxart — Merger or Acquisition (October 2017)
12 slides from Vaxart's merger presentation, Oct 30, 2017
Slide 1: Aviragen Therapeutics and Vaxart Joint Conference Call
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call U N LO C K I N G T H E F U L L P OT E N T I A L O F O R A L VAC C I N ES October 30, 2017
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements about Aviragen Therapeutics, Inc. and Vaxart Inc., and their respective businesses, business prospects, strategy and plans, including but not limited to statements regarding anticipated preclinical and clinical drug development activi
Slide 3: Additional Information About the Merger and Where to Find It
Additional Information About the Merger and Where to Find It In connection with the merger, Aviragen and Vaxart intend to file relevant materials with the Securities and Exchange Commission, or the SEC, including a registration statement on Form S-4 that will contain a prospectus and a joint proxy s
Slide 4: About the Transaction
About the Transaction • Aviragen Therapeutics, Inc. valuation $60M • Vaxart, Inc. valuation $90M • Aviragen stockholders 40%/Vaxart stockholders 60% • Seven board members – three from Aviragen • Company name will be Vaxart • Proposed NASDAQ ticker – “VXRT” • Approximately $30M in cash projected at c
Slide 5: Oral Recombinant Vaccines
ORAL RECOMBINANT VACCINES INNOVATIVE TABLET OFFERS HIGH VALUE VACCINE PLATFORM ADVANTAGES PIPELINE • Designed for wide range of • Room temperature-stable • Norovirus Phase 1b recombinant antigens tablet successfully completed • Broad immune responses • Ease of distribution, - 100% responders - Syste
Slide 6: Oral Recombinant Vaccine Platform
Oral Recombinant Vaccine Platform Non-Replicating Ad5 Delivers Antigen + Adjuvant VACCINE ANTIGEN • Gene for protein antigen VACCINE • Released in Ileum generates - Influenza HA Ad5 VECTOR broad immune responses - Norovirus VP1 • Replication - RSV F protein deficient - HPV E6/E7 proteins TLR3 ADJUVA
Slide 7: Global Vaccines Market: $30 Billion+ Annual Sales
Global Vaccines Market: $30 Billion+ Annual Sales • “Vaccines are among big Vaccine Blockbusters (2015) pharma’s best selling products” – – FT, April 26 2016 $ 6.2 billion • Vaccine Growth Trends $ 1.9 billion – Innovation – Elderly/Adult Vaccination $ 1.5 billion – Vaccination for New Diseases $ 1.
Slide 8: Veteran Management Team with Deep Experience in Vaccines and Immunology
Veteran Management Team with Deep Experience in Vaccines and Immunology RELEVANT EXPERIENCE MANAGEMENT TEAM (YEARS) COMPANIES EXPERTISE Vaccines, Mucosal WOUTER LATOUR, MD MBA 20 Delivery of CEO Biopharmaceuticals SEAN TUCKER, PHD Mucosal Immunology 20 Gene Delivery Founder and CSO GMP Manufacturing
Slide 9: Robust Antiviral Clinical Pipeline Focused on Both Prophylactic and Therapeutic Products
Robust Antiviral Clinical Pipeline Focused on Both Prophylactic and Therapeutic Products Trials Conducted to Date or in Progress Tablet Vaccine Preclinical Phase 1 Phase 2 Phase 3 Marketed Prophylactic Norovirus 1) Influenza 2) RSV Therapeutic HPV Vaccine Small Molecules HPV (BTA074) Rhinovirus (Vap
Slide 10: Norovirus: Tablet is Key Differentiator
Norovirus: Tablet is Key Differentiator Major ‘Consumer’ Opportunity in Food and Travel Sector Disease Burden 1) • Norovirus leads to majority of Acute Gastroenteritis – 19-21 Million Cases, 56,000-71,000 Hospitalizations – 570-800 Deaths (all US numbers) • Increasing disease awareness from CDC netw
Slide 11: Safety and Broad Immune Responses in Multiple Trials
Safety and Broad Immune Responses in Multiple Trials More than 300 Subjects Dosed to Date CLINICAL TRIALS Tablet Vaccines Flu RSV Norovirus SUBJECTS DOSED 176 46 106 SAFETY Favorable safety and tolerability profile EFFICACY Reduction in influenza illness comparable with the leading marketed quadriva
Slide 12: Clinical & Regulatory Milestones
Clinical & Regulatory Milestones Recently Completed ü Q3 2017 - Reported positive top-line data from Phase 1b norovirus vaccine safety and immunogenicity trial ü Q3 2017 – Reported positive top-line data from Phase 2 influenza vaccine challenge trial Upcoming • Q4 2017 - Complete enrollment in Phase